{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T08:32:12Z","timestamp":1770280332775,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"51","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772192"],"award-info":[{"award-number":["81772192"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.vaccine.2019.09.073","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T23:57:55Z","timestamp":1569542275000},"page":"7501-7508","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1\/V2 region or V3 crown deletion"],"prefix":"10.1016","volume":"37","author":[{"given":"Ming","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengfeng","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4936-1718","authenticated-orcid":false,"given":"Robin J","family":"Shattock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinxue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2019.09.073_b0005","doi-asserted-by":"crossref","first-page":"e1241","DOI":"10.3390\/ijms19041241","article-title":"HIV Vaccination: a roadmap among advancements and concerns","volume":"19","author":"Trovato","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.vaccine.2019.09.073_b0010","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/COH.0000000000000363","article-title":"Stabilized HIV-1 envelope glycoprotein trimers for vaccine use","volume":"12","author":"Medina-Ramirez","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.vaccine.2019.09.073_b0015","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ebiom.2017.05.029","article-title":"HIV-specific B cell frequency correlates with neutralization breadth in patients naturally controlling HIV-infection","volume":"21","author":"Rouers","year":"2017","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.vaccine.2019.09.073_b0020","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.coi.2012.04.006","article-title":"HIV vaccine design: the neutralizing antibody conundrum","volume":"24","author":"Stamatatos","year":"2012","journal-title":"Curr Opin Immunol"},{"issue":"30","key":"10.1016\/j.vaccine.2019.09.073_b0025","doi-asserted-by":"crossref","first-page":"12111","DOI":"10.1073\/pnas.1204533109","article-title":"HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120","volume":"109","author":"Kovacs","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"10.1016\/j.vaccine.2019.09.073_b0030","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1084\/jem.20161160","article-title":"Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo","volume":"214","author":"Medina-Ramirez","year":"2017","journal-title":"J Exp Med"},{"issue":"6133","key":"10.1016\/j.vaccine.2019.09.073_b0035","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1126\/science.1234150","article-title":"Rational HIV immunogen design to target specific germline B cell receptors","volume":"340","author":"Jardine","year":"2013","journal-title":"Science"},{"issue":"6280","key":"10.1016\/j.vaccine.2019.09.073_b0040","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1126\/science.aad9195","article-title":"HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen","volume":"351","author":"Jardine","year":"2016","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.vaccine.2019.09.073_b0045","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1586\/14760584.2014.894469","article-title":"Targeting B-cell germlines and focusing affinity maturation: the next hurdles in HIV-1-vaccine development?","volume":"13","author":"Medina-Ramirez","year":"2014","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"10.1016\/j.vaccine.2019.09.073_b0050","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1084\/jem.20122824","article-title":"Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies","volume":"210","author":"McGuire","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2019.09.073_b0055","doi-asserted-by":"crossref","first-page":"e37688","DOI":"10.7554\/eLife.37688","article-title":"Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core","volume":"7","author":"Borst","year":"2018","journal-title":"Elife"},{"issue":"8","key":"10.1016\/j.vaccine.2019.09.073_b0060","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1371\/journal.ppat.0030117","article-title":"V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies","volume":"3","author":"Laakso","year":"2007","journal-title":"PLoS Pathog"},{"issue":"5","key":"10.1016\/j.vaccine.2019.09.073_b0065","doi-asserted-by":"crossref","first-page":"e0152038","DOI":"10.1371\/journal.pone.0152038","article-title":"Comparative immunogenicity of HIV-1 gp140 vaccine delivered by parenteral, and mucosal routes in female volunteers; MUCOVAC2, a randomized two centre study","volume":"11","author":"Cosgrove","year":"2016","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.vaccine.2019.09.073_b0070","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.4049\/jimmunol.1300120","article-title":"CCL19 and CCL28 augment mucosal and systemic immune responses to HIV-1 gp140 by mobilizing responsive immunocytes into secondary lymph nodes and mucosal tissue","volume":"191","author":"Hu","year":"2013","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.09.073_b0075","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.virol.2011.11.023","article-title":"Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction","volume":"423","author":"Huang","year":"2012","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.vaccine.2019.09.073_b0080","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1128\/JVI.03473-14","article-title":"A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene","volume":"89","author":"Pugach","year":"2015","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2019.09.073_b0085","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.celrep.2015.03.047","article-title":"Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design","volume":"11","author":"Sharma","year":"2015","journal-title":"Cell Rep"},{"issue":"15","key":"10.1016\/j.vaccine.2019.09.073_b0090","doi-asserted-by":"crossref","first-page":"7760","DOI":"10.1128\/JVI.76.15.7760-7776.2002","article-title":"Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency Virus Type 1 gp140 envelope glycoprotein","volume":"76","author":"Schulke","year":"2002","journal-title":"J Virol"},{"issue":"6","key":"10.1016\/j.vaccine.2019.09.073_b0095","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1128\/JVI.02380-15","article-title":"Immunogenicity of a prefusion HIV-1 envelope trimer in complex with a quaternary-structure-specific antibody","volume":"90","author":"Cheng","year":"2015","journal-title":"J Virol"},{"issue":"24","key":"10.1016\/j.vaccine.2019.09.073_b0100","doi-asserted-by":"crossref","first-page":"e01216","DOI":"10.1128\/JVI.01216-17","article-title":"Functional stability of HIV-1 envelope trimer affects accessibility to broadly neutralizing antibodies at its apex","volume":"91","author":"Gift","year":"2017","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2019.09.073_b0105","doi-asserted-by":"crossref","first-page":"e1003618","DOI":"10.1371\/journal.ppat.1003618","article-title":"A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies","volume":"9","author":"Sanders","year":"2013","journal-title":"PLoS Pathog"},{"issue":"6","key":"10.1016\/j.vaccine.2019.09.073_b0110","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.vaccine.2010.11.084","article-title":"Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen","volume":"29","author":"Arias","year":"2011","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2019.09.073_b0115","doi-asserted-by":"crossref","first-page":"e25165","DOI":"10.1371\/journal.pone.0025165","article-title":"Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally","volume":"6","author":"Lewis","year":"2011","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.vaccine.2019.09.073_b0120","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1089\/aid.2007.0131","article-title":"Immunogenicity comparison between codon optimized HIV-1 CRF BC_07 gp140 and gp145 vaccines","volume":"23","author":"Liu","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.vaccine.2019.09.073_b0125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12985-014-0221-0","article-title":"HIV-1 vaccine immunogen design strategies","volume":"12","author":"Mann","year":"2015","journal-title":"Virol J"},{"issue":"1","key":"10.1016\/j.vaccine.2019.09.073_b0130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/imr.12512","article-title":"Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem","volume":"275","author":"Havenar-Daughton","year":"2017","journal-title":"Immunol Rev"},{"issue":"14","key":"10.1016\/j.vaccine.2019.09.073_b0135","doi-asserted-by":"crossref","first-page":"9069","DOI":"10.1128\/JVI.79.14.9069-9080.2005","article-title":"The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner","volume":"79","author":"Saunders","year":"2005","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2019.09.073_b0140","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1074\/jbc.RA117.000709","article-title":"Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers","volume":"293","author":"de Taeye","year":"2018","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.vaccine.2019.09.073_b0145","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/ni.3158","article-title":"Antibody responses to envelope glycoproteins in HIV-1 infection","volume":"16","author":"Burton","year":"2015","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2019.09.073_b0150","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.4049\/jimmunol.160.11.5676","article-title":"The effect of deletion of the V3 Loop of gp120 on cytotoxic T cell responses and HIV gp120-mediated pathogenesis","volume":"9","author":"Kmieciak","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.09.073_b0155","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1128\/JVI.67.8.4557-4565.1993","article-title":"Functional and immunologic characterization of human immunodeficiency virus Type 1 envelope glycoproteins containing deletions of the major variable regions","volume":"9","author":"Wyatt","year":"1993","journal-title":"J Virol"},{"issue":"6215","key":"10.1016\/j.vaccine.2019.09.073_b0160","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1126\/science.1259206","article-title":"Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies","volume":"346","author":"McGuire","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2019.09.073_b0165","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1146\/annurev-immunol-020711-075032","article-title":"Germinal centers","volume":"30","author":"Victora","year":"2012","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2019.09.073_b0170","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1084\/jem.20120150","article-title":"Germinal center B cells govern their own fate via antibody feedback","volume":"210","author":"Zhang","year":"2013","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.vaccine.2019.09.073_b0175","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jmb.2003.10.007","article-title":"Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures","volume":"334","author":"Zemlin","year":"2003","journal-title":"J Mol Biol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.09.073_b0180","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/imr.12075","article-title":"HIV-1 neutralizing antibodies: understanding nature's pathways","volume":"254","author":"Mascola","year":"2013","journal-title":"Immunol Rev"},{"issue":"2","key":"10.1016\/j.vaccine.2019.09.073_b0185","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0022-2836(02)01222-6","article-title":"Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen","volume":"325","author":"Collis","year":"2003","journal-title":"J Mol Biol"},{"issue":"12","key":"10.1016\/j.vaccine.2019.09.073_b0190","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.4049\/jimmunol.174.12.7773","article-title":"Development of the expressed Ig CDR-H3 repertoire is marked by focusing of constraints in length, amino acid use, and charge that are first established in early B cell progenitors","volume":"174","author":"Ivanov","year":"2005","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.09.073_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/prot.340160102","article-title":"Length Distribution of CDRHS in Antibodies","volume":"16","author":"Wu","year":"1993","journal-title":"Proteins"},{"issue":"15","key":"10.1016\/j.vaccine.2019.09.073_b0200","doi-asserted-by":"crossref","first-page":"e00603","DOI":"10.1128\/JVI.00603-17","article-title":"Anti-HIV-1 ADCC antibodies following latency reversal and treatment interruption","volume":"91","author":"Lee","year":"2017","journal-title":"J Virol"},{"issue":"12","key":"10.1016\/j.vaccine.2019.09.073_b0205","doi-asserted-by":"crossref","first-page":"e1006786","DOI":"10.1371\/journal.ppat.1006786","article-title":"eCD4-Ig promotes ADCC activity of sera from HIV-1-infected patients","volume":"13","author":"Davis-Gardner","year":"2017","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2019.09.073_b0210","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.3389\/fimmu.2018.02613","article-title":"Identification of a HIV Gp41-specific human monoclonal antibody with potent antibody-dependent cellular cytotoxicity","volume":"9","author":"Yang","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2019.09.073_b0215","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3389\/fimmu.2019.00677","article-title":"Induction of Fc-mediated effector functions against a stabilized inner domain of HIV-1 gp120 designed to selectively harbor the A32 epitope region","volume":"10","author":"Visciano","year":"2019","journal-title":"Front Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19313015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19313015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T23:09:19Z","timestamp":1695251359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19313015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":43,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0264410X19313015"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.073","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1\/V2 region or V3 crown deletion","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.09.073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}